Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine

Linyun Tan; Yitian Wang; Xin Hu; Guifeng Du; Xiaodi Tang; Li Min

doi:10.3390/biom13091362

Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine

Biomolecules. 2023 Sep 7;13(9):1362. doi: 10.3390/biom13091362.

Authors

Linyun Tan^{1

2}, Yitian Wang^{1

2}, Xin Hu^{1

2}, Guifeng Du^{1

2}, Xiaodi Tang^{1

2}, Li Min^{1

2}

Affiliations

¹ Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu 610064, China.
² Department of Model Worker and Innovative Craftsman, West China Hospital, Sichuan University, Chengdu 610064, China.

Abstract

The management of osteosarcoma (OS) patients presents a significant clinical challenge. Despite progress in conventional and targeted therapies, the survival rate of OS patients remains limited largely due to therapy resistance and the high metastatic potential of the disease. OS models that accurately reflect the fundamental characteristics are vital to the innovation and validation of effective therapies. This review provides an insight into the advances and challenges in OS drug development, focusing on various preclinical models, including cell lines, 3D culture models, murine models, and canine models. The relevance, strengths, and limitations of each model in OS research are explored. In particular, we highlight a range of potential therapeutics identified through these models. These instances of successful drug development represent promising pathways for personalized OS treatment.

Keywords: 3D culture technology; canine models; cell lines; drug discovery; mice models; osteosarcoma models.

Publication types

Review

Grants and funding

This work was supported by the Sichuan Science and Technology Agency, grant number 2022NSFSC0845.